Georgian Scientists/ . 6 N 1, 2024 58 Georgian Scientists Vol. 6 Issue 1, 2024 https://doi.org/10.52340/gs.2024.06.01.09 - ¹, 2 , , , ORCID ID: 0009-0003-5181-424X 2 , , , , . , , . , , , . : , , , , , , , , , , . 350 . Georgian Scientists/ . 6 N 1, 2024 59 , , , . , . , [1,2]. , . , , [2]. , , . , . 100-1000- . , , ( 1) 1. ( 2) Georgian Scientists/ . 6 N 1, 2024 60 2. . . , . . . , , , , , , [3, 4]. . , . , Georgian Scientists/ . 6 N 1, 2024 61 , . , . . , (Similar Biotherapeutic Products, SBPs) . , , . , . , - . , , , [5,7]. (WHO) , , , “ [8]. (EMA) , „ , , ). ( ) , , , .“[9]. , , : ( ). . “. Georgian Scientists/ . 6 N 1, 2024 62 „ “ . . „ “ , , . „ “, , . (head to head) . , “ , “ , [9-13]. , , , . , , , . ( 3) 3. ( 2004 , 2009 ) Georgian Scientists/ . 6 N 1, 2024 63 . . . : , , , . . , , - . , [14]. (mAbs) (mAbs) , , . mAb , , , . ( 6) mAb- ( ) .mAb- -mAb . mAb- . [14]. Georgian Scientists/ . 6 N 1, 2024 64 6. Steven Kozlowski, Director OBP, FDA , , . . , . , , . : 1. , . Georgian Scientists/ . 6 N 1, 2024 65 2. , . 3. , , . 4. , , , . „ “ , (head to head) , , . 5. , , . 6. . : 1. EMA. Biological Medicines https://www.ema.europa.eu/en/glossary/biological-medicine Accessed December. 2023 2. FDA. Biological Product Definitions https://www.fda.gov/files/drugs/published/Biological-Product-Definitions.pdf Accessed December, 2023 3. Manufacturing Process of Biologics https://www.ema.europa.eu/en/documents/presentation/presentation-manufacturing-process- biologics-kowid-ho-afssaps_en.pdf Accessed December, 2023 4. Arnold G. Vulto, Orlando A. Jaquez - The process defines the product: what really matters in biosimilar design and production? Rheumatology 2017;56:iv14iv29 doi:10.1093/rheumatology/kex278 5. EMA. Generic and Hybrid Medicines Georgian Scientists/ . 6 N 1, 2024 66 https://www.ema.europa.eu/en/human-regulatory-overview/marketing-authorisation/generic- and-hybrid-medicines. Accessed December, 2023 6. FDA. Generic Drugs https://www.fda.gov/drugs/buying-using-medicine-safely/generic-drugs. Accessed December, 2023 7. FDA. Biosimilars. https://www.fda.gov/drugs/therapeutic-biologics-applications-bla/biosimilars. Accessed December, 2023 8. Guidelines on evaluation of similar biotherapeutic products (SBPs). In: WHO Expert Committee on Biological Standardization: Sixtieth report. Geneva: World Health Organization; 2013: Annex 2 (WHO Technical Report Series, No. 977; http://www.who.int/biologicals/publications/trs/areas/biological_therapeutics/TRS_977_Annex_ 2.pdf, accessed December 2023). 9. EMA. Biosimilars overview. https://www.ema.europa.eu/en/human-regulatory- overview/biosimilar-medicines-overview. Accessed December 2023 10. EMA. Similar biological medicinal products- Scientific guideline https://www.ema.europa.eu/en/similar-biological-medicinal-products-scientific-guideline. Accessed December, 2023 11. EMA. Biosimilars in EU. https://www.ema.europa.eu/en/documents/leaflet/biosimilars-eu- information-guide-healthcare-professionals_en.pdf Accessed December, 2023 12. ICH Q5E Biotechnological/biological products subject to changes in their manufacturing process: comparability of biotechnological/biological products – Scientific guidelinehttps://www.ema.europa.eu/en/ich-q5e-biotechnological-biological-products-subject- changes-their-manufacturing-process-comparability-biotechnological-biological-products- scientific-guideline. Accessed December, 2023 13. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline. Specifications: test procedures and acceptance criteria for biotechnological/biological products Q6B. 1999 guideline recommended for adoption https://www.ema.europa.eu/en/ich-q6b-specifications-test- procedures-and-acceptance-criteria-biotechnological-biological-products-scientific-guideline. Accessed December 2023 14. EMA. Immunogenicity assessment of biotechnology-derived therapeutic proteins – Scientific guideline. https://www.ema.europa.eu/en/immunogenicity-assessment-biotechnology-derived- therapeutic-proteins-scientific-guideline. Accessed December, 2023 15. WHO. Monoclonal Antibodies (mABs) https://www.who.int/teams/health-product-policy-and- standards/standards-and-specifications/monoclonal-antibodies. Accessed December, 2023 Georgian Scientists/ . 6 N 1, 2024 67 Biologic and Chemical Medicines – Differences in Terms of Basic Scientific and Regulatory Aspects Nino Ganugrava, Marika Megrelishvili Abstract Biological Medicines represent an innovative advance in Healthcare, offering targeted and immunotherapies for a wide range of complex diseases. In this scientific article, we aim to present the fundamental differences between biological and chemical medicines in terms of mechanism of action, manufacturing process and regulatory environment. Additionally, we will discuss the basic scientific aspects of biosimilar and generic medicines, focusing on their regulatory details, which have a significant impact on patients care and healthcare system Keywords: Biological Medicine, Chemical Medicine, Biosimilars, Generic Medicines, Regulatory Environment, Monoclonal Antibodies